论文部分内容阅读
据美国WedMD大众医疗新闻网(2010-02-18)报道,为了让转移性肾细胞癌(metastatic renal cell carcinoma,RCC)的标靶治疗有最佳效果,旧药的新数据确认了将细胞白介素-2(IL-2)和氟尿嘧啶加入干扰素alfa-2a,并没有比单用干扰素治疗有更佳的存活率。
According to the United States WedMD Public Medical News (2010-02-18) reported that in order to make targeted therapy of metastatic renal cell carcinoma (RCC) the best results, the new data of the old drug confirmed the interleukin -2 (IL-2) and fluorouracil to interferon alfa-2a did not have a better survival rate than interferon alone.